Rebound thymic hyperplasia after pneumonectomy and chemotherapy for primary synovial sarcoma.
Thymic hyperplasia occurs in a small proportion of patients receiving chemotherapy for various malignancies. It likely results from an immunologic rebound phenomenon. Fluorodeoxyglucose positron emission tomography-computed tomography is an important tool for staging malignant neoplasms. We report a case of rebound thymic hyperplasia manifesting as a hypermetabolic mass on fluorodeoxyglucose positron emission tomography-computed tomography after pneumonectomy and chemotherapy for primary pulmonary synovial sarcoma. We highlight the importance of recognizing the phenomenon of rebound thymic hyperplasia, as it can mimic residual or recurrent malignancy, especially in the setting of altered chest anatomy.
Ford
Meghan E
ME
College of Medicine, The Ohio State University Medical Center, Columbus, OH 43210, USA. Meghan.Ford@osumc.edu
Stevens
Robert
R
Rosado-de-Christenson
Melissa L
ML
Hall
Nathan C
NC
Suster
Saul
S
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D009367:Neoplasm Staging; D011013:Pneumonectomy; D049268:Positron-Emission Tomography; D013584:Sarcoma, Synovial / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D013952:Thymus Hyperplasia / Q000000981:diagnostic imaging / Q000628:therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004317:Doxorubicin; D007069:Ifosfamide